Company Overview and News
Investors in TransEnterix, Inc. (TRXC - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $5.00 Put had some of the highest implied volatility of all equity options today.
GM.WS.A GM.WS.B GM.WS.C TRXC GM GM.WSB PII
TransEnterix, Inc. (TRXC - Free Report) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $3.13 to $4.78 in the past one-month time frame. The company has not seen any estimate revisions over the past month, while the Zacks Consensus Estimate for the current quarter also remained unchanged.
ATEC TRXC DY ICHR
The overall bioscience market ended the week with a mixed sentiment. Nevertheless, many firms under our coverage continued to post further gains for investors.
EIDX TRXC ISRG IBB XBI
Are you ready? Artificial intelligence (AI) isn’t just for tech companies. Biotech stocks are also capitalizing on AI’s potential to deliver revolutionary drugs and speed up drug discovery. A recently released report by Accenture reveals that AI in healthcare could become a $6.6 billion industry by 2021. This is up from just $600 million in 2014.
IBM JNJ GOOGL GMED TRXC GOOG MDT
Aduro Biotech Inc. (ADRO) is a smallcap with a market capitalization of $533.397M. The company develops immunotherapy drugs, focuses on development of therapies that treat challenging diseases. The Berkeley, CA based company was founded as Oncologic, Inc. in 2000 and renamed to Aduro BioTech, Inc. in June 2008.
MNKD SCD IRWD CMRX TRXC K CLRBZ CLRBW OPHT ADRO FGEN JNJ IOVA LPCN CLRB PFE BMY
Louisiana State University recently purchased a Senhance. This is the sixth unit sold this year. Senhance has many key advantages over Intuitive Surgical's da Vinci (for fostering strong upcoming growth).
The global bariatric surgery devices market is expected to reach USD 2.8 billion by 2022, according to a new report by Grand View Research, Inc. The growing incidence rate of obesity has led to many government initiatives at regional as well as global level to increase the awareness related to obesity and undertake various incidence curbing action plans. For instance, the South Wales government launched the NSW Healthy Eating and Active Living Strategy 2013-2018 for preventing obesity.
GIDYL AGN IREHF AGN.PRA TRXC ISRG IRI ACT GID
TransEnterix is powered by Senhance, a next-generation robotic system for abdominal laparoscopic surgery. Senhance has many key advantages over the reigning champion, da Vinci of Intuitive Surgical.
FONR TRXC ISRG
The overall bioscience market gave up some gains Tuesday after four consecutive bullish sessions. Many equities under our coverage continue to rack up further gains.
TRXC ISRG IBB XBI
2017-11-07 - Asif
TransEnterix, Inc. is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical challenges associated with current laparoscopic and robotic options. TransEnterix is focused on the commercialization and further development of its Senhance™ Surgical Robotic System (formerly known as the ALF-X ® Surgical Robotic System) (the “Senhance System”), a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology. The Senhance System has been granted a CE Mark in Europe for laparoscopic abdominal and pelvic surgery, as well as limited thoracic operations excluding cardiac and vascular surgery, but is not available for sale in the U.S. TransEnterix has also developed the SurgiBot™ System (the “SurgiBot System”), a single-port, robotically enhanced laparoscopic surgical platform. The SurgiBot System is not available for sale in any market. The Senhance...
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to TRXC / TransEnterix, Inc. on message board site Silicon Investor.
as of ET